المؤلفون: Zeng, Zhiyong^{Aff1, Aff2, Aff3, IDs4139202401941x_cor1}, Yang, Apeng, Yang, Jingke, Zhang, Sheng, Xing, Zhen, Wang, Xingfu, Mei, Wenzhong, Jiang, Changzhen, Lin, Junfang, Wu, Xiyue, Xue, Yihui, Wu, Zanyi, Yu, Lianghong, Wang, Dengliang, Chen, Jianwu, Zheng, Shufa, Lin, Qiaoxian, Chen, Qingjiao, Dong, Jinfeng, Zheng, Xiaoqiang, Wang, Jizhen, Huang, Jinlong, Chen, Zhenying, Chen, Ping, Zheng, Meihong, Zhou, Xiaofang, He, Youwen, Lin, Yuanxiang^{Aff7, IDs4139202401941x_cor28}, Chen, Junmin^{Aff1, Aff2, Aff3, IDs4139202401941x_cor29}

المصدر: Signal Transduction and Targeted Therapy. 9(1)

المؤلفون: Ren, Jinhua, Lin, QiaoXian, Chen, Qi, Xu, Jingjing, Chen, Dabin, Chen, Renli, Lin, Kangni, Zhu, Haojie, Ye, Chenjing, Luo, Xiaofeng, Chen, Shaozhen, Kong, Hui, Lin, Qiong, Li, Nan, Lin, Xu, Chen, Zhizhe, Hu, Jianda, Yang, Ting

المصدر: In iScience 17 March 2023 26(3)

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Ren, Jinhua^Aff1, Lin, Qiaoxian^{Aff1, Aff2}, Chen, Weimin^Aff3, Lin, Congmeng^Aff4, Zhang, Yuxin^Aff1, Chen, Cunrong^Aff5, Chen, Shaozhen^Aff1, Yuan, Xiaohong^Aff1, Chen, Ping^Aff1, Luo, Xiaofeng^Aff1, Lin, Yun^Aff3, Shen, Lvying^Aff4, Guo, Mengxian^Aff4, Chen, Qiuru^Aff1, Xiao, Min^Aff1, Chen, Yongquan^Aff1, Wu, Xueqiong^Aff1, Zeng, Yanling^{Aff1, Aff6}, Chen, Zhizhe^Aff1, Ma, Xudong^Aff4, Hu, Jianda^Aff1, Yang, Ting^Aff1

المصدر: European Journal of Clinical Microbiology & Infectious Diseases. 38(5):865-876

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Yang T; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Lin Q; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Ren J; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Chen P; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Yuan X; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Luo X; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Liu T; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Zheng J; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Zheng Z; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Zheng X; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Chen X; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Zhang L; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Zheng H; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Chen Z; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Hua X; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Le S; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Li J; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Chen Z; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China., Hu J; Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, P. R. China.

المصدر: Oncotarget [Oncotarget] 2016 Nov 29; Vol. 7 (48), pp. 78773-78786.

نوع المنشور: Journal Article; Observational Study

بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/adverse effects , Hematopoietic Stem Cell Transplantation*/mortality , Neoadjuvant Therapy*/adverse effects , Neoadjuvant Therapy*/mortality, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Hematologic Neoplasms/*therapy , Transplantation Conditioning/*methods, Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Busulfan/administration & dosage ; Chemotherapy, Adjuvant ; Child ; Child, Preschool ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Disease Progression ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Hematologic Neoplasms/genetics ; Hematologic Neoplasms/mortality ; Hematologic Neoplasms/pathology ; Humans ; Infant ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Proportional Hazards Models ; Recurrence ; Remission Induction ; Time Factors ; Transplantation Conditioning/adverse effects ; Transplantation Conditioning/mortality ; Transplantation, Haploidentical ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives ; Young Adult